<DOC>
	<DOC>NCT00395486</DOC>
	<brief_summary>The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.</brief_summary>
	<brief_title>ROMEO (Rosuvastatin in Metabolic syndrOme)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Presence of 3 or more of the following criteria; Abdominal obesity (men &gt;90cm women &gt;80cm) Triglycerides ≥ 150 mg/dL HDLC: men &lt; 40 mg/dL, women &lt; 50 mg/dL BP ≥130/≥85 mmHg or antihypertensive treatment Fasting blood glucose ≥100 mg dL or antidiabetic treatment Elevated LDLC ; ≥130 mg/dL to &lt; 220 mg/dL in lipid lowering agent naive subjects ≥100 mg/dL to &lt; 200 mg/dL in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1. Triglyceride &lt; 500 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>rosuvastatin</keyword>
	<keyword>lipoprotein</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>